<DOC>
	<DOCNO>NCT00006786</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Bevacizumab may stop growth colorectal cancer stop blood flow tumor . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus bevacizumab treating patient advance colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Bevacizumab Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine progression-free survival 7 month patient previously untreated advanced colorectal cancer treat fluorouracil , leucovorin calcium , irinotecan , bevacizumab . II . Determine response rate overall survival patient population treat regimen . III . Determine toxicity treatment regimen patient . OUTLINE : This multicenter study . Patients receive irinotecan IV 90 minute , leucovorin calcium IV , fluorouracil IV weekly 4 week . Patients also receive bevacizumab IV 30-90 minute every 2 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 75 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced metastatic adenocarcinoma colon rectum Surgically unresectable disease Measurable disease Disease outside prior radiotherapy port and/or progressive disease within previously irradiate volume PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 No hemorrhagic event within past 6 month Hepatic : Bilirubin normal SGOT normal INR great 1.5 Renal : Creatinine great 1.5 time upper limit normal Cardiovascular : No thromboembolic event within past 6 month Pulmonary : No evidence pneumonia Other : No known hypersensitivity recombinant humanize murine monoclonal antibody No evidence significant active infection ( e.g. , peritonitis wound abscess ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent sargramostim ( GMCSF ) Chemotherapy : At least 12 month since prior fluorouracilbased adjuvant chemotherapy No prior adjuvant irinotecan Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy recover Surgery : See Disease Characteristics Other : No prior therapy advance disease No concurrent therapeutic anticoagulation except lowdose coumadin maintenance indwell catheter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>